0.05Open0.03Pre Close1 Volume877 Open Interest1.50Strike Price5.00Turnover197.42%IV57.84%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.2373Delta0.7014Gamma19.64Leverage Ratio-0.0036Theta0.0001Rho4.66Eff Leverage0.0007Vega
Ocugen Stock Discussion
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate Ocu410St for Treatment of Abca4-Associated Retinopathies Including Stargardt Disease
Ocugen Announces Compelling Preliminary Data for Ocu410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
No comment yet